Ipamorelin vs Tesamorelin: What the Evidence Shows

01Short Answer

Ipamorelin vs Tesamorelin: The Short Answer

Ipamorelin vs tesamorelin has a short answer: tesamorelin has two phase 3 trials and one FDA-approved use, and ipamorelin has neither. The two act on different receptors, so neither is a stronger version of the other.

Tesamorelin is a synthetic growth hormone-releasing hormone, or GHRH, and binds the GHRH receptor on the pituitary. Ipamorelin copies ghrelin and acts on the growth hormone secretagogue receptor instead. Both raise growth hormone by different routes, and the evidence behind each route is not equivalent.

Protocol Health prescribes compounded ipamorelin and offers tesamorelin under clinician supervision when appropriate, so we have a commercial interest in both and say so plainly. You can start the assessment to find out whether either is worth a conversation.

In short, tesamorelin is an approved drug with one narrow proven use, and ipamorelin is an unapproved compounded peptide whose human record is a single trial that missed its endpoint.

02The Difference

What Is the Difference Between Ipamorelin and Tesamorelin?

The difference between ipamorelin and tesamorelin is the receptor each one targets and the amount of human evidence behind it.

Tesamorelin keeps all 44 amino acids of human GHRH and adds a hexenoyl group to the first amino acid, according to the Egrifta SV prescribing information. That group stabilizes the molecule, and it is often marketed as making tesamorelin long-acting. The label puts the mean elimination half-life at 8 minutes in healthy subjects after a single subcutaneous dose, which is not what long-acting usually implies.

Ipamorelin is far smaller. The 1998 paper that introduced it describes a pentapeptide, five amino acids, that released growth hormone in rat pituitary cells, anesthetized rats and conscious swine with potency similar to GHRP-6. That paper is also the origin of ipamorelin's reputation for selectivity: unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol even at more than 200 times the dose that released growth hormone. Those were animals, and the selectivity claim that sells ipamorelin has never been confirmed in a human efficacy trial.

Bottom line. For each molecule alone, see our guides to what ipamorelin is and what tesamorelin is. The practical difference between ipamorelin and tesamorelin is that one has a reviewed label and a trial dossier, and the other has a marketing story.

03FDA Status

Are Ipamorelin and Tesamorelin FDA-Approved?

Tesamorelin is FDA-approved for exactly one use, and ipamorelin is not FDA-approved for any use at all.

Tesamorelin: approved for one narrow indication

Tesamorelin is approved for one narrow indication: the Egrifta SV label states it is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label's own limitations of use add that long-term cardiovascular safety has not been established and that the drug "is not indicated for weight loss management as it has a weight neutral effect." Any use outside HIV-associated lipodystrophy is off-label, and a compounded tesamorelin is not FDA-approved.

Ipamorelin: never approved, and flagged by the FDA

Ipamorelin has never been approved by the FDA for any use, and the agency has flagged it. Ipamorelin acetate appears on the FDA's list of bulk drug substances that may present significant safety risks. The reasons given are specific: compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities," it "contains unnatural amino acids, which add to the complexity of peptide characterization," and "a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility." The FDA adds that it lacks sufficient information to know whether ipamorelin would cause harm by other injectable routes.

Bottom line. Being compounded is not being approved. The FDA states in its compounding questions and answers that compounded drugs are not FDA-approved, so the agency does not verify their safety, effectiveness or quality before marketing. On FDA status the two are not close: tesamorelin has an approval and a reviewed label, and ipamorelin has a safety notice.

04Tesamorelin Evidence

What Do the Tesamorelin Trials Show?

The tesamorelin trials show a dependable but narrow effect: less visceral fat in adults with HIV-associated lipodystrophy, and little established beyond it.

Two phase 3 trials randomized 806 antiretroviral-treated adults with excess abdominal fat in a 2:1 ratio to tesamorelin or placebo, and the trials administered 2 mg subcutaneously once daily. In the pooled analysis, visceral adipose tissue fell by 24 cm2 on tesamorelin against a 2 cm2 rise on placebo at week 26, a treatment effect of 15.4%. Abdominal subcutaneous fat did not change significantly. Triglycerides fell with a treatment effect of 12.3%, and mean IGF-1 rose by 108 ng/mL.

The larger individual trial followed 404 patients for 12 months, with visceral fat down about 11% at six months and roughly 18% at twelve. It also recorded what peptide marketing leaves out: patients switched from tesamorelin to placebo rapidly lost the reduction they had gained. The effect depends on continued treatment.

Evidence outside lipodystrophy is thin but real. A 12-month randomized trial in 61 people with HIV and non-alcoholic fatty liver disease found hepatic fat fraction fell by an absolute 4.1%, a 37% relative reduction, with 35% of the tesamorelin group under a 5% hepatic fat fraction against 4% on placebo. A secondary analysis of the phase 3 data found patients whose visceral fat fell at least 8% also had better triglycerides, fasting glucose and HbA1c.

Bottom line. Every one of those trials studied people with HIV. That is the population the tesamorelin trials show a benefit in, and no phase 3 trial has tested tesamorelin in otherwise healthy adults for body composition or aging.

05Ipamorelin Evidence

What Does the Ipamorelin Evidence Show?

The ipamorelin evidence shows very little in humans, and the only efficacy trial that exists is one that failed.

Ipamorelin has reached only two published human trials, and neither tested a clinical outcome it is sold for. The first was a 1999 dose-escalation study in 40 healthy men, five infusion rates with eight subjects each, which confirmed that ipamorelin releases growth hormone in humans, peaking about 40 minutes after the infusion (Gobburu and colleagues, Pharmaceutical Research, 1999, PMID 10496658). It measured hormone release, not a clinical result. The second was the only efficacy trial, and it failed. A phase 2, multicenter, double-blind, placebo-controlled study enrolled 117 adults undergoing small or large bowel resection and tested intravenous ipamorelin against placebo for postoperative ileus. The study administered 0.03 mg/kg twice daily from postoperative day 1 until discharge. Median time to tolerating a standardized solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant, with a p value of 0.15.

That trial is the high-water mark of ipamorelin's human record, and it was a miss. Ipamorelin was not carried forward into an approved drug. Apart from that 1999 pharmacokinetic study, the rest of the literature is preclinical, including the 1998 work in rats and swine and a rodent gastroparesis model in which ipamorelin accelerated gastric emptying after abdominal surgery. Notice what those studies chased: ipamorelin's development aimed at gut motility, not at the body composition, fat loss or anti-aging it is sold for today.

Bottom line. No published trial has tested ipamorelin for visceral fat, lean mass, sleep quality or skin in humans. A PubMed search for ipamorelin and tesamorelin together in the title or abstract returned seven records as of October 2026, every one a narrative review or clinician primer and none a comparative trial. The ipamorelin evidence shows an interesting animal profile and a single human trial that did not meet its endpoint.

06Which Is Better

Is Ipamorelin or Tesamorelin Better?

Whether ipamorelin or tesamorelin is better has no trial-based answer, because no study has compared them, and the honest version of the question is approved drug against unapproved peptide.

The two bodies of evidence are not the same size. Tesamorelin brings 806 patients of phase 3 data, an approval and a documented 15% reduction in visceral fat in one defined population. Ipamorelin brings 117 patients in a phase 2 trial that missed its endpoint, no approval and an FDA safety notice. That is a difference in evidence, not proof that ipamorelin does nothing.

Comparing percentages across those trials does not close the gap, because one measured abdominal fat on CT over six months and the other measured hours to a tolerated meal after bowel surgery.

Bottom line. If one is better for a particular person, that is a prescriber's judgment against labs and history rather than a fact the literature supplies. On published evidence alone, tesamorelin is the better documented of the two.

07By Goal

Ipamorelin vs Tesamorelin for Fat Loss, Muscle Growth and Sleep

For fat loss, muscle growth and sleep, ipamorelin vs tesamorelin comes down to separating what patients hope for from what trials measured.

• Visceral fat. Tesamorelin reduced visceral fat by about 15% over 26 weeks in adults with HIV-associated lipodystrophy. Ipamorelin has never been tested for visceral fat in a published human trial.
• Weight loss. Neither peptide is a weight-loss medicine. The Egrifta SV label states it is not indicated for weight loss management because it has a weight neutral effect, and ipamorelin has no human weight-loss data at all.
• Muscle growth. Patients often seek ipamorelin or tesamorelin for muscle growth, and controlled trials have not confirmed it for either. Tesamorelin's phase 3 trials were designed around visceral fat, and ipamorelin's only human trial measured recovery of bowel function.
• Sleep. Patients often ask about ipamorelin for sleep, and no published human trial has measured sleep quality on either peptide.
• Appetite. Ipamorelin acts on the ghrelin receptor, the pathway that signals hunger, so an appetite effect is biologically plausible and has not been quantified in a published human efficacy trial.

Bottom line. Resistance training, adequate protein and consistent sleep remain the levers with consistent evidence for muscle and recovery. For fat loss, muscle growth and sleep, controlled human trials support tesamorelin for visceral fat in one population, and ipamorelin for none of the three.

08Side Effects

Ipamorelin and Tesamorelin Side Effects and Safety Risks

Ipamorelin and tesamorelin side effects differ mainly in how well they are documented, and the safety risk profile of ipamorelin is the less measured of the two.

The Egrifta SV label lists the most common adverse reactions, each in more than 5% of patients, as arthralgia, injection site erythema, injection site pruritus, pain in the extremity, peripheral edema and myalgia. Its warnings cover increased risk of neoplasms, elevated IGF-1 with the note that the effects of prolonged elevation are unknown, fluid retention including edema and carpal tunnel syndrome, glucose intolerance or diabetes, hypersensitivity reactions, and increased mortality in acute critical illness. Prescribers are instructed to monitor IGF-1 and evaluate glucose before and during therapy. The label contraindicates tesamorelin in disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to the drug or its excipients, and pregnancy, because modifying visceral fat offers no benefit in pregnancy and could cause fetal harm.

Ipamorelin has no FDA-reviewed label, so no equivalent list exists. The phase 2 ileus trial reported treatment-emergent adverse events in 87.5% of the ipamorelin arm and 94.8% of placebo, in surgical inpatients where that rate says little about outpatient use. The FDA's safety entry is the more useful document: immunogenicity risk from aggregation and peptide-related impurities, difficulty characterizing a peptide containing unnatural amino acids, and serious adverse events including death reported with intravenous administration.

Bottom line. Both peptides raise growth hormone and IGF-1, so it is reasonable to assume the tesamorelin label's growth-hormone cautions apply to ipamorelin too, and nobody has confirmed that. Neither has long-term safety data in healthy adults. If you develop swelling, persistent joint pain, numbness or tingling in the hands, or signs of an allergic reaction, contact a clinician promptly and see our safety information page. The side effects of tesamorelin are catalogued, while the safety risks of ipamorelin are largely unmeasured.

09Together

Can You Take Ipamorelin and Tesamorelin Together?

No published trial has tested taking ipamorelin and tesamorelin together, so the combination has no evidence behind it.

The pharmacology does give a reason someone would try. Tesamorelin acts on the GHRH receptor and ipamorelin on the ghrelin receptor, so the two signals are additive at the pituitary rather than duplicative, which is the rationale behind every GHRH-plus-secretagogue blend sold online. Plausible is not tested.

Bottom line. The known risks scale with growth hormone and IGF-1 exposure, and the Egrifta SV label states the effects of prolonged IGF-1 elevation are unknown. Stacking two pathways raises that exposure with no trial showing what it buys, so taking ipamorelin and tesamorelin together is a prescriber's decision made against labs rather than something to assemble independently.

10CJC-1295

Tesamorelin vs CJC-1295 and Ipamorelin

Tesamorelin vs CJC-1295 and ipamorelin is the comparison most people actually mean, because ipamorelin is usually sold blended with CJC-1295 rather than on its own.

CJC-1295 is a modified GHRH analog, so a CJC-1295 and ipamorelin blend pairs a GHRH signal with a ghrelin signal. Measured against that blend, tesamorelin is the only one of the three with an FDA approval and phase 3 data. CJC-1295 has no FDA-approved version either and is available only as a compounded, unapproved drug. Our CJC-1295 and ipamorelin guide covers that combination, and our sermorelin vs tesamorelin comparison covers the other GHRH analog people weigh against Egrifta.

Bottom line. No trial has compared tesamorelin with a CJC-1295 and ipamorelin blend, so tesamorelin vs CJC-1295 and ipamorelin is settled on regulatory status and trial evidence rather than on a head-to-head result.

11Our Approach

Ipamorelin vs Tesamorelin at Protocol Health

Protocol Health approaches ipamorelin or tesamorelin as a physician-led practice, which means a clinician decides whether either belongs in your plan before anything is prescribed.

In-person visits take place in Scarsdale, New York, and telehealth is available in NY, NJ, CT, FL and CA. A peptide consultation starts with your history, medications, goals and labs where indicated, before any prescription is considered. To start, take the Protocol Health quiz.

Protocol Health prescribes compounded ipamorelin and offers tesamorelin when a clinician judges either appropriate, and the clinic has a commercial interest in that decision. Ipamorelin is not FDA-approved for any use and appears on the FDA's list of bulk substances that may present significant safety risks. Egrifta is FDA-approved only for excess abdominal fat in HIV-associated lipodystrophy, any other use is off-label, and compounded tesamorelin is not FDA-approved. Some people who ask about either peptide are better served by a different plan, and a consultation can end with that advice.

Bottom line. Ipamorelin vs tesamorelin compares an unapproved peptide with one failed human trial against an approved drug with a narrow, well-documented use: 806 patients of phase 3 evidence behind a roughly 15% visceral fat reduction in adults with HIV-associated lipodystrophy, against animal pharmacology plus an FDA safety notice. No trial has compared them. This article is educational and is not a substitute for individualized medical advice; suitability, dose and monitoring are decided with a qualified clinician who knows your full picture.

FAQ

Frequently Asked Questions

Explore

Related at Protocol Health

• Tesamorelin Therapy →
• Ipamorelin Therapy →
• What Is Tesamorelin? →
• What Is Ipamorelin? →
• Sermorelin vs Tesamorelin →